Free Webinar Series
Join us in the lead up to Animal Health Innovation Europe 2021 with our series of free webinars featuring speakers from Paul Dick & Associates, Klifovet AG, and Elanco.
Webinar Series Calendar
20 January, 2021 at 2:00pm EST
10 February, 2021 at 2:00pm EST
Why Attend?
Animal Health Innovation Europe is the sector’s premier investment forum in Europe showcasing the most exciting innovators in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners.
To complement our investment pitches, we include keynote presentations and host CEO-level panel discussions that address the trends and market dynamics of the animal health industry, across all species.
Our virtual format gives us a unique opportunity with our programming in 2021 to involve a wider array of stakeholders and key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians and farmers today.
Book now to come and see for yourself!
Innovation Showcase
Innovation Showcase Finalists 2021 have been announced!
Click here to find out who will be pitching.
Speakers
Jeff Simmons
Kristin Peck
Kristin Peck was appointed Chief Executive Officer of Zoetis in January 2020. In this role, she leads the world’s leading animal health company, a Fortune 500 organization with approximately $6 billion in annual revenue and 10,000 employees worldwide. Ms. Peck is also a member of the Zoetis Board of Directors.
Prior to becoming CEO, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at Zoetis. Ms. Peck helped usher Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in many roles at the company including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research.
Before joining Zoetis, Ms. Peck served as executive vice president, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. In this role, she was responsible for the evaluation of strategic alternatives for Pfizer's Animal Health and Nutrition businesses – paving the way for a public animal health company and attractive investment opportunity.
Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.
Ms. Peck is a member of the Business Roundtable, and also serves on the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. She previously served as a member of the Thomson Reuters’ Board of Directors. As a recipient of the 2019 Feather in Her Cap Award, Ms. Peck has been recognized for her leadership and contributions to the animal health industry, and her work in mentoring women and helping them advance their careers in animal health.
Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School.
Tina Hunt
Christine Middlemiss
Jean Scheftsik de Szolnok
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Richard Hobson
Dr. Jamie Crittall
Jamie qualified from Bristol Vet School in 1993. He owns two separate UK veterinary practices – one, a family-owned 146-year old multi-branch practice and the other, a 7-year old start-up (which he has subsequently sold in December 2018), as well as global healthcare compliance technology company, Virtual Recall.
Co-Founded with fellow veterinarian, Charlie Barton, as a result of their vision to enhance the intimate bond between all owners & their animals. They help vets create more valued customer experiences and drive improved business performance, to deliver better health and financial outcomes. They currently have their patent-pending, communication solution, iRecall® installed in over 1300 practices worldwide. It enables practices to send their clients their own bespoke messages, completely automatically, ensuring every animal and every client receive the appropriate communication - including immediate feedback - every time.
iRecall® has sent over 15 million automated and personalized messages by SMS, email & post this year to over 2.5 million clients. helping them to become better informed and more engaged in the health and well-being of their 4.5 million animals, driven by their vets’ recommendations. Improving compliance, adherence and greater practice loyalty, delivering a virtuous value circle.
iRecall® also enhances practices’ digital reputations by capturing over 370 000 Net Promoter Scores, with an average score of over 80, with promoters encouraged to provide written testimonials and online reviews.
Jamie also has an all-encompassing knowledge and love for the media, being vet on set for film, tv & commercials for twenty plus years and a 5-year sabbatical in British television. He appeared regularly as a vet on The Big Breakfast; Sky News; BBC1’s The Really Useful Show, and latterly, co-presenting Pet Rescue’s spin off series, Pet Rescuers and Pet Rescue Roadshow. He has radio broadcast countrywide and is a regular speaker at UK veterinary business, technology and marketing seminars, conferences and events. Jamie is a Trustee of the Petplan Charitable Trust. Married with three children and a menagerie of pets and he can often be found mountain biking around the Surrey Hills.
Robert Dawson
Davide Rossi
Davide Rossi is a Co-Founder and CEO of FitBark, a data-driven pet technology company focused on getting pets and their owners safe and healthy together. FitBark builds collar sensors and software infrastructure that helps humans in 140+ countries to develop real-time, comparative knowledge of their pet’s location, activity, quality of sleep, calorie balance, anxiety, skin conditions and overall health and behavior. FitBark is also a research-grade platform adopted by 100+ vet schools and research institutions to conduct research on new drugs, products and treatments related to mobility, anxious behaviors and skin conditions.
In a previous life, Davide designed Ferrari engines, co-founded BRM Model Cars, and managed Oil & Gas projects in Asia and the Middle East. More recently, he served as an investment banker with Deutsche Bank in New York, where he advised FinTech clients on capital raises and matters related to mergers and acquisitions.
Davide holds a M.S. in Mechanical Engineering from Università degli Studi di Padova (Italy) and a Master in Business Administration from the Massachusetts Institute of Technology.
Dr. Jude Capper
Aidan Connelly
Tim Pfister
Sandhya Sriram
Wesley Wierson
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Kamran Adle
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Phil Wilkinson
Lyndsay Chapman
Amanda Burkardt
Matt Dobbs
Gudrun Ravetz
Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.
Lauren Carde
Laëtitia Gerbe
Joost Matthijssen
Patricia Barclay
Jason Clay
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Kevin Cook
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Daniella Dos Santos
Daniella obtained a BSc (hons) in Molecular Genetics from Kings College London in 2007, before going to study veterinary medicine at the RVC, qualifying in 2012. Since then she has been in first opinion small animal and exotic animal practice and is currently working towards her CertAVP zoological medicine. She became a member of the BVA Ethics and Welfare Advisory Panel in 2015, and became Chair in 2017. She also became a Trustee of the Animal Welfare Foundation in 2016.
Jo Malone
Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.
In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.
In 2015 she became Managing Director of VetPartners and then CEO in 2016.
Rob Kelly
Dave Ross
Gilles Guillemette
Caroline Povey
Charlie Sheppy
Sophie Throup
Tom Zerzan
Joseph Harvey
Deb Sharkey
Deb Sharkey is the chief consumer officer for Covetrus. She oversees marketing, product and strategy for Covetrus’ Global Technology Services and the SmartPak brand. Deb has extensive ecommerce experience in both large company and tech startup environments with a particular expertise in multi-customer marketplaces. Her previous roles include vice president at eBay and chief operating officer of DogVacay, which was acquired by Rover.com. Deb holds degrees from the University of Virginia and the University of Technology Sydney.
Photo Gallery
Photos from February 2020 now available to download and share - view the full photo gallery here.
Advisory Board
Author:
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Author:
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Author:
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Author:
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Author:
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Author:
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Selection Committee
Author:
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Author:
Matthias Hofer
Matthias Hofer is a business leader with broad international experience and strength in sales, strategy and execution. He served on the executive committees of 2 major Animal Health companies for a total of 7 years.
Matthias lives in Switzerland with his wife and his two children. After completing his Master‘s degree at the University of St.Gallen (HSG), he started working for Novartis Animal Health (NAH) in Sydney, Australia in a project support role, serving the APAC region.
In 2006, Matthias was promoted first to Strategic Planning Manager for NAH and from there to Head of Strategy for the Animal Health Division. Between 2009 – 2013 Matthias led NAH’s Aqua Health business globally. This business today is amongst the top few companies in the Aqua-health industry.
During 2014 and with Elanco’s intention to buy NAH, Matthias served as integration leader for NAH on the Novartis side. In that role Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Once Elanco and NAH successfully merged, Matthias took on the role as Global Leader Emerging Business within Elanco. In that function Matthias was responsible for a total of five fast growing business areas, including Aqua, Vaccines, Enzymes and others.
Most recently Matthias has joined Stonehaven Consulting Group as a partner.
Stonehaven
Author:
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Author:
Maarten Goossens
Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management.
Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture.
Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.
Author:
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Author:
Paul Dick
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Author:
Sarai Kemp
As VP Business Development for Trendlines Agtech since 2012, Sarai Kemp is responsible for directing the business and financial development and fund-raising strategies and activities for early-stage portfolio companies developing innovative technologies and products in aquaculture, food production, biopesticides and agrochemicals, and other related sectors. Trendlines Agtech is part of The Trendlines Group (www.trendlines.com). Trendlines invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies, and is involved in all aspects of its portfolio companies from technology development to business building.
Sarai brings more than 12 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.
Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.
Author:
Tom Prins
Tom manages the process of screening new business opportunities for Aqua-Spark and negotiating new investments. He has been directly involved throughout the investment process for the majority of the current Aqua-Spark portfolio, ranging from investments in feed ingredients, technology, health, genetics and production. Tom joined Aqua-Spark in 2015. Prior to Aqua-Spark, he worked in the Gulf region with the Netherlands Agricultural Attaché for GCC countries and the Netherlands Embassy in the Sultanate of Oman, where he conducted research on the development of local aquaculture industry. He has also spearheaded transnational events to elevate public and private dialogue on emerging opportunities in aquaculture. Tom received a Master in Business Geography from Utrecht University. A fervent surfer, Tom is dedicated to conserving the ocean for future generations.
Agenda
Download the 2021 agenda
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Download the 2021 agenda
Partners
Animal Health Innovation Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.
Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health Investment series.
Headline Partner
Elanco
Website: http://www.elanco.com
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.
Associate Digital Innovation Partner
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Platinum Digital Innovation Partners
Boehringer Ingelheim
Website: http://www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
GHO Capital
Website: http://ghocapital.com
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare private equity firm based in London. GHO Capital works with ambitious management teams of profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. The Firm’s 2015 vintage fund – GHO Capital Fund I LP – has been raised to seize the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment and industry skills which sets the Firm apart from traditional private equity firms. For further information, please visit www.ghocapital.com.
Phibro Animal Health Corporation
Website: http://www.pahc.com
Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal protein. We are a global diversified animal health and mineral nutrition company. We concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. For nearly 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition.
Knowledge Partner
McKinsey & Company
Website: https://www.mckinsey.com
McKinsey & Company is a global management consulting firm committed to helping organizations create Change that Matters.
In more than 130 cities and 65 countries, our teams help clients across the private, public and social sectors shape bold strategies and transform the way they work, embed technology where it unlocks value, and build capabilities to sustain the change. Not just any change, but Change that Matters – for their organizations, their people, and in turn society at large.
Consulting Partner
Stonehaven Consulting
Website: http://www.stonehaven-consulting.com
Stonehaven Consulting AG was founded in 2015 as a specialist Life Science management consultancy firm. Based in Switzerland, we provide international consulting services to all sectors in Life Sciences.
We are especially interested in assisting ambitious clients wishing to commercialise new technologies or leverage opportunities for growth. We do this by following a unique approach where we not only help our clients to develop the best possible strategy but partner with them to bring it to life – we are happy to share risks and opportunities. We are an experienced group of individuals with a long track record of successful operational and strategic management on many levels and for a number of multinational Animal Health companies as well as companies in Life Sciences.
Our founder, George Gunn has served as CEO for a number of companies and our other members of the team bring complementary skills and experience to our group. All of us have substantial experience and background in Animal Health – an industry we are very excited about.
Start-Up Development Partner
Paul Dick and Associates (PDA)
Website: http://pauldickassociates.com
Paul Dick & Associates Ltd. (PDA), founded in 2010, is an animal health consulting firm specializing in (1) the creation of strategic business and product life plans, (2) product development and regulatory affairs strategies, (3) the conduct of GCP studies, (4) the development of white papers to support marketing and sales, (5) business development and fundraising, (6) the acquisition and pitching of new technologies, actives and products, and, (7) various other supporting activities for product development and commercialization. The capabilities of Paul Dick & Associates Ltd. span the research, development, regulatory, and, commercialization continuum for animal pharmaceuticals, biologicals, vaccines, feed ingredients and feeds, and natural/ low risk health products. PDA is the recognized expert for these matters in Canada, as well as for other global markets.
Gold Digital Innovation Partners
OCR
Website: http://www.oncovet-clinical-research.com
OCR is a full-Vet CRO based in Lille-France, with a know-how on every steps of the clinical development and registration of a product for the pets market. OCR is specialized in clinical studies on severe diseases affecting dogs and cats: cancer, and others diseases in therapeutic areas like inflammation, cardiology, dermatology, antibiotic resistance, neurology. Along with a highly experienced team (clinical project leaders, RCA, data managers, biostatisticians, and veterinary specialist consultants), OCR built a European network of veterinary clinics with high level technical platform, including imaging (CT-scan, MRI, scintigraphy) and radiation therapy units and vet specialist strongly involved in clinical research. Our expertise in a nutshell: conception of the study with vet experts, determining pre-clinical and clinical development plans, conducting Proof-of-Concept studies, Pilot and Pivotal studies, site selection, laboratory identification and management, regulatory affairs, data management & biostatistics, VICH GCP clinical studies standards. Strong track record with the vet industry with pilot/pivotal studies, as well as with biotech/pharma through comparative medicine studies.
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com/ or connect with us on LinkedIn and Twitter.
Bonaccord
Website: https://www.bonaccord.law/
Bonaccord is an award winning law firm established to support the scientific community. They help innovative businesses maximise the commercial value of their technologies and have particular expertise in the life sciences, specialty chemicals and advanced engineering.
Nutreco NuFrontiers
Website: http://www.nutreconufrontiers.com
Nutreco is a global leader in animal nutrition and aquafeed. Our advanced nutritional solutions are at the origin of food for millions of consumers worldwide. Nutreco employs over 12,000 people in 35 countries with net sales of over € 6 billion. Our two global company brands Skretting (aquafeed) and Trouw Nutrition (animal nutrition) have sales in over 90 countries. Innovation sits at the very heart of Nutreco’s business and culture. Through our strategic innovation and investment division Nutreco NuFrontiers, we look to identify, develop and invest in next generation, sustainable products, models and services throughout the feed and food protein value chain. NuFrontiers invests both in start-ups developing new technologies, ingredients or formulations, and joint-ventures and partnerships to create ‘moonshot projects’ that address major bottlenecks in the feed and food value chain. For more information visit www.nutreco.com and www.nutreconufrontiers.com
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Skills Alliance
Website: https://www.skillsalliance.com/
Skills Alliance believe in creating long-term partnerships with their clients as it enables them to provide tailored offerings to match your time and budget requirements.
With a network of offices in London, Zurich, New York, Seattle and Newport Beach and their partnership with Unique Group to cover Latin and South America, they’re able to provide a dynamic combination of local expertise and a global search capability.
They continually evaluate, invest in and implement all suitable new technology (including AI) to ensure you always receive the most cost-effective and efficient fulfilment of your brief. Cutting-edge businesses require a recruitment capability that leads the field.
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
Animalcare Group
Website: https://www.animalcaregroup.com/
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition
ZENOAQ
Website: http://www.zenoaq.jp/english/index.html
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
knoell
As one of the leading service providers for worldwide registration and regulatory compliance knoell offers you efficient services, high flexibility, excellent quality, and reliability. The knoell group has over 600 experts based in 14 countries supporting you to gain and maintain marketability of your substances, active agents, and products - globally! Our team of scientific and regulatory experts can help you in animal health, crop protection, crop nutrition, chemicals, biocides, and medical devices. The knoell approach to acting worldwide is your key to success. Think Globally, Act Locally!
APHA Scientific
Website: http://www.aphascientific.com
Animal and Plant Health Agency (APHA) are an internationally recognised centre of scientific excellence providing a wide range of research and consultancy to the UK Government and commercial customers. We specialise in diseases of livestock and plants, diagnosis of disease and surveillance of new and emerging disease. APHA has achieved world reference laboratory status for a number of animal diseases.
To enhance its scientific activity APHA develops commercial products and services and makes them available to organisations globally. These are brought together under APHA Scientific to ensure the products and services are delivered effectively to customers.
Our products and services include:
- Biological reagents and test kits
- Proficiency testing (VETQAS)
- Wildlife management and radar detection
- Laboratory testing
- Vaccine development and testing
- Virus discovery
- Pathology and bio-imaging
- Bacterial identification and characterisation
- Veterinary research and development
- Access to Animal and Plant Health Agency intellectual property.
For more information about any of our services please contact
T: 03000 600001
E: [email protected]
www.aphascientific.com
IDEXX
Website: http://www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Gnubiotics
Website: https://gnubiotics.com/
Gnubiotics Sciences is a biotech company pioneering, research, development and industrialization of essential animal milk oligosaccharides (AMOs) to support companion animal GI, immune and microbiome health.
Syngene
Website: http://www.syngeneintl.com
Syngene International Ltd. is an innovation focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000- strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speedup time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.
Covetrus
Website: https://softwareservices.covetrus.com/emea/
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. A company passionate about advancing the world of veterinary medicine with big goals when it comes to delivering the best in animal care. As a newly formed and global company, they bring together products, services, and technology into a single platform, connecting their customers to the solutions and insights they need to work best.
Silver Event Partner
Vetigenics
Website: http://www.vetigenics.com/
Vetigenics creates novel immunotherapies to treat cancer and other chronic conditions in dogs without the debilitating side effects. Our fully canine phage display platform, enables rapid isolation of unique antibody fragments (scFvs) or CANIBODIES™ to any antigen based binding affinity, functionality and developability. CANIBODIES™ are entirely generated from naïve, canine germline genes, don't require costly, time-consuming caninization and can be readily engineered into mAbs, BiTEs or CAR-T therapies. As a result, our therapies are designed for precision efficacy and lack of immunogenicity, not possible with other discovery technologies. Vetigenics is advancing three internally developed antibody products into the clinic with our 1st in dog studies starting during 1Q21.
Roslin Technologies
Website: https://roslintech.com/
Roslin Technologies is a cutting-edge biotech company that transforms science innovations to provide solutions to global challenges in AgTech and animal health through our expertise in stem cell science and genomic technologies.
Roslin Technologies is a joint venture between the University of Edinburgh and two investment and business development partners with a strong global network and reach. We are based in the Midlothian Science Zone, one of the largest animal science innovation hubs in the world, ensuring that the company is well placed to exploit ground-breaking innovations in animal science and AgTech.
We are currently looking for partners in the animal therapies space with an interest in utilising our Canine induced pluripotent stem cell lines.
Media Partners
IAHJ - International Animal Health Journal
Website: http://www.animalhealthmedia.com
IAHJ - International Animal Health Journal is a Peer reviewed by our carefully selected editorial advisory panel, and extensive research network, IAHJ reports on Regulations & Validation, Drug Discovery, Development & Delivery, Clinical Research, Nutrition & Infectious Diseases, Custom & Contract Manufacturing, Primary & Secondary Packaging, Logistics & Supply Chain Management, and Marketing & Authorisation of all Drugs, Devices and Food Products that are used in the treatment of animals.
Vet Record
Website: https://veterinaryrecord.bmj.com/
Veterinary Record (branded as Vet Record) is the official journal of the British Veterinary Association (BVA) and has been published weekly since 1888. It contains news, opinion, letters, scientific reviews and original research papers and communications on a wide range of veterinary topics, along with disease surveillance reports, obituaries, careers information, business and innovation news and summaries of research papers in other journals. It is published on behalf of the BVA by BMJ Group.
eFeed Link
Website: http://www.efeedlink.com
All About Feed
Website: http://www.allaboutfeed.net
All About Feed is a true multimedia brand, bringing you the latest developments in animal nutrition, diet formulation, and feed processing equipment. We deliver the best articles right in your inbox - subscribe for our e-mail newsletter by clicking here.
Pharma Journalist
Website: http://www.pharmajournalist.com
Pharma Journalist is a leading international B2B magazine providing the global information and the recent updates in the Pharmaceutical Industry.
Our editorial staff works dedicatedly to provide latest information of Pharmaceutical Industry in the form of articles, news, trends, analysis, market report, press releases, whitepapers, case studies, etc. which helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Various Online marketing services and promotional activities through Pharma Journalist helps companies and organizations to reach their target audience and create brand awareness.
Pet Business World
Website: http://www.petbusinessworld.co.uk
Pet Business World is the UK’s leading news magazine and website for the pet and aquatics industry. We distribute 7,711 copies (November 2018) to qualifying pet trade professionals – the biggest circulation in the specialist trade by a considerable margin. The independently-owned magazine was established in 1951 and the website (www.petbusinessworld.co.uk) attracted more than 37 million hits in the 12 months to October 2018 – and rising!
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Press Partnerships
Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:
- Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
- Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
- Provide one free press pass to attend
- Distribute promotional materials at the conference
If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:
Sarah Rowlands
Senior Marketing Manager
T: +44 (0)203 696 2920
E: sarah.rowlands@kisacoresearch.com
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.